WellSpan Home

Health Library

Von Hippel-Lindau Syndrome

What is von Hippel-Lindau syndrome (VHL)?

Two eye healthcare providers—von Hippel in Germany and Lindau in Sweden—were the first to publish descriptions of tumors in patients' eyes and brains, hallmarks of this genetic condition. In the 1960s, the disease was named von Hippel-Lindau syndrome to recognize their contributions in characterizing the condition.

Von Hippel-Lindau syndrome is a rare genetic disorder characterized by an increased risk of developing the tumors listed below:

  • Hemangioblastomas. Benign (noncancerous) tumors made up of nests of blood vessels of the brain and spine.

  • Hemangioblastomas of the retina

  • Pheochromocytomas. A neuroendocrine tumor, usually benign (noncancerous), within or outside of the adrenal gland

  • Renal cell carcinoma. Cancerous tumor of the kidney that happens in about 70% of individuals with VHL. 

Less commonly, some individuals develop endolymphatic sac tumors (ear tumors that can cause deafness if undetected), pancreatic tumors, and cystadenomas of the epididymis or broad ligament. Other signs include cysts (pockets of fluid) of the kidney and pancreas.

The VHL gene is a tumor suppressor gene located on chromosome 3. This usually controls cell growth and cell death. Both copies of a tumor suppressor gene must be changed, or mutated, before a person will develop cancer. In about 80% of VHL cases, the first mutation is inherited from either the mother or the father. It is present in all cells of the body at birth. This is called a germline mutation. Whether a person who has a germline mutation will develop a tumor and where the tumor(s) will develop depends on where (in which cell type) the second mutation happens. For example, if the second mutation is in the retina, then a retinal hemangioblastoma may develop. If it is in the adrenal gland, then a pheochromocytoma may develop. The process of tumor development actually needs mutations in multiple growth control genes. Loss of both copies of the VHL gene is just the first step in the process. What causes these additional mutations is unknown. Possible causes include chemical, physical, or biological environmental exposures or chance errors in cell replication.

Some individuals who have inherited a germline VHL mutation never develop cancer. This is because they never get the second mutation necessary to knock out the function of the gene and start the process of tumor formation. This can make the cancer appear to skip generations in a family. But, in reality, the mutation is present. Individuals with a VHL mutation, regardless of whether they develop cancer, have a 50/50 chance to pass the mutation on to each of their children. About 20% of VHL cases are new mutations, and not inherited from a parent.

It is also important to remember that the VHL gene is not located on the sex chromosomes. Therefore, mutations can be inherited from either the mother's side or the father's side of the family.

Molecular genetic testing of VHL is available and identifies a mutation in about 90% to 100% of affected people. Genetic testing is also considered part of the standard management for first-degree relatives (parent, siblings, children) of affected people. For people who are mutation-positive, annual screening to find tumors before severe complications develop is recommended. Genetic testing of unaffected relatives is useful only if a germline mutation has already been identified in an affected family member.

Von Hippel-Lindau Syndrome - WellSpan Health

Online Medical Reviewer: Dozier, Tennille, RN, BSN, RDMS
Online Medical Reviewer: Levin, Mark, MD
Last Review Date: 2015-12-22T00:00:00
Last Modified Date: 2016-03-22T00:00:00
Posting Date: 2008-11-30T00:00:00
Published Date: 2016-03-22T00:00:00
Last Review Date: 2012-06-07T00:00:00
© 2016 WellSpan Health. All Rights Reserved. This information is not intended as a substitute for professional medical care. Always follow your healthcare professional's instructions.

I would like to:

Are you sure you would like to cancel?

All information will be lost.

Yes No ×

About the provider search

This search will provide you with WellSpan Medical Group and Northern Lancaster County (Ephrata) Medical Group primary care physicians and specialists. If we don’t have a WellSpan Medical Group physician to meet your criteria, the search will expand to include community physicians who partner with WellSpan Medical Group physicians through the WellSpan Provider Network or provide care to patients on the Medical Staffs of WellSpan’s Hospitals.


Schedule Your Next Appointment Online with MyWellSpan

Use your MyWellSpan patient portal any time to view available appointments, and pick the date and time that best suits your schedule.

Go to MyWellSpan

New to this practice?

If you don't have a WellSpan primary care provider and would like to schedule a new patient appointment with a provider who is accepting patients, just log into your MyWellSpan account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to see the offices that are accepting new patients in relation to your zip code. If you are not enrolled in MyWellSpan, go to https://my.wellspan.org, call 1-866-638-1842 or speak with a member of the staff at a participating facility to sign up. New patient scheduling not available at all practices/programs.

Already a patient at this practice?

If you already have a relationship with a WellSpan practice, simply log into your account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to schedule an appointment with any provider or practice that already counts you as a patient. Online scheduling varies by practice/program.